BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32920821)

  • 1. Evaluating multiple surrogate markers with censored data.
    Parast L; Cai T; Tian L
    Biometrics; 2021 Dec; 77(4):1315-1327. PubMed ID: 32920821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating surrogate marker information using censored data.
    Parast L; Cai T; Tian L
    Stat Med; 2017 May; 36(11):1767-1782. PubMed ID: 28088843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust methods to correct for measurement error when evaluating a surrogate marker.
    Parast L; Garcia TP; Prentice RL; Carroll RJ
    Biometrics; 2022 Mar; 78(1):9-23. PubMed ID: 33021738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a surrogate marker for early testing of a treatment effect.
    Parast L; Cai T; Tian L
    Biometrics; 2019 Dec; 75(4):1253-1263. PubMed ID: 31009073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust approach to combining multiple markers to improve surrogacy.
    Wang X; Parast L; Han L; Tian L; Cai T
    Biometrics; 2023 Jun; 79(2):788-798. PubMed ID: 35426444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the feasibility of shortening clinical trial duration using surrogate markers.
    Wang X; Cai T; Tian L; Bourgeois F; Parast L
    Stat Med; 2021 Dec; 40(28):6321-6343. PubMed ID: 34474500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doubly robust evaluation of high-dimensional surrogate markers.
    Agniel D; Hejblum BP; Thiébaut R; Parast L
    Biostatistics; 2023 Oct; 24(4):985-999. PubMed ID: 35791753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust estimation of the proportion of treatment effect explained by surrogate marker information.
    Parast L; McDermott MM; Tian L
    Stat Med; 2016 May; 35(10):1637-53. PubMed ID: 26631934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flexible evaluation of surrogate markers with Bayesian model averaging.
    Duan Y; Parast L
    Stat Med; 2024 Feb; 43(4):774-792. PubMed ID: 38081586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing heterogeneity in surrogacy using censored data.
    Parast L; Tian L; Cai T
    Stat Med; 2024 May; ():. PubMed ID: 38812276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonparametric inverse-probability-weighted estimators based on the highly adaptive lasso.
    Ertefaie A; Hejazi NS; van der Laan MJ
    Biometrics; 2023 Jun; 79(2):1029-1041. PubMed ID: 35839293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for heterogeneity in the utility of a surrogate marker.
    Parast L; Cai T; Tian L
    Biometrics; 2023 Jun; 79(2):799-810. PubMed ID: 34874550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of longitudinal surrogate markers.
    Agniel D; Parast L
    Biometrics; 2021 Jun; 77(2):477-489. PubMed ID: 32506496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.
    Zhou RR; Zhao SD; Parast L
    Stat Med; 2022 May; 41(12):2227-2246. PubMed ID: 35189671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the value of a censored surrogate outcome.
    Parast L; Tian L; Cai T
    Lifetime Data Anal; 2020 Apr; 26(2):245-265. PubMed ID: 30980316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the Relation Between G-formula and Inverse Probability Weighting Estimators for Generalizing Trial Results.
    Dahabreh IJ; Robertson SE; Hernán MA
    Epidemiology; 2019 Nov; 30(6):807-812. PubMed ID: 31517670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doubly robust nonparametric instrumental variable estimators for survival outcomes.
    Lee Y; Kennedy EH; Mitra N
    Biostatistics; 2023 Apr; 24(2):518-537. PubMed ID: 34676400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying surrogate markers in real-world comparative effectiveness research.
    Han L; Wang X; Cai T
    Stat Med; 2022 Nov; 41(26):5290-5304. PubMed ID: 36062392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doubly-robust methods for differences in restricted mean lifetimes using pseudo-observations.
    Choi S; Choi T; Lee HY; Han SW; Bandyopadhyay D
    Pharm Stat; 2022 Nov; 21(6):1185-1198. PubMed ID: 35524651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double Robust Efficient Estimators of Longitudinal Treatment Effects: Comparative Performance in Simulations and a Case Study.
    Tran L; Yiannoutsos C; Wools-Kaloustian K; Siika A; van der Laan M; Petersen M
    Int J Biostat; 2019 Feb; 15(2):. PubMed ID: 30811344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.